In a retrospective cohort of 139,608 US veterans, GLP-1 receptor agonists showed no significant increase in incident depression (RR 1.02, 95% CI 0.97-1.07) compared to DPP-4 inhibitors within 1 year of starting treatment — addressing safety concerns raised by FDA warnings.
RR 1.02 (not significant)After adjusting for all confounders, GLP-1 RA users had essentially the same depression risk as DPP-4i users — no increase detected in 139,608 patients over 7 years
What the researchers found
Incident depression within 1 year: GLP-1 RA group 7.7% (2,263/34,130) vs DPP-4i group 6.3% (6,602/105,478). Adjusted relative risk: 1.02 (95% CI: 0.97-1.07, not significant). All sensitivity analyses also non-significant.
Why it matters
FDA labeling warnings about suicidal thoughts and behaviors on GLP-1 weight-loss drugs have caused significant patient and clinician concern. This large real-world study provides reassuring evidence that GLP-1 drugs don't increase depression risk — critical safety data as millions of people start these medications.
The numbers in context
Study period: June 2013 to June 2020. Compared GLP-1RA vs. DPP-4 inhibitor initiators in the Veterans Health Administration.
How the study worked
Retrospective cohort study using VA healthcare data (June 2013-June 2020). 34,130 GLP-1 RA initiators vs 105,478 DPP-4i initiators. Primary outcome: incident depression (new diagnosis or new antidepressant) within 1 year. Multivariable log-binomial regression adjusting for demographics, comorbidities, prior medications.
Who was studied
US veterans initiating GLP-1RA vs. DPP-4 inhibitors (2013-2020)
What this study cannot tell us
Retrospective observational design — cannot prove causation. VA population is predominantly male and older, limiting generalizability. Depression detection relies on diagnosis codes and antidepressant prescriptions, which may miss cases. Only 1-year follow-up. Did not separate individual GLP-1 RAs or doses. DPP-4i comparator may also have mental health effects.
How to read the evidence
Rated strong: large cohort (139K patients), 7-year study period, robust statistical adjustment, and active comparator design. Limited by retrospective/observational nature.
When this study was published
Published in 2024. Directly addresses current FDA safety labeling concerns for GLP-1 weight loss drugs.
The bigger picture
As GLP-1 drugs are prescribed to millions for diabetes and obesity, resolving safety concerns about psychiatric effects is critical. This study joins growing evidence that GLP-1 drugs may actually improve mental health through weight loss and metabolic improvements, rather than worsening it — though continued pharmacovigilance is warranted.
Questions still open
- Should the FDA suicidal ideation warning be reconsidered given accumulating negative evidence?
- Do specific GLP-1 RAs (semaglutide vs liraglutide vs dulaglutide) differ in psychiatric effects?
- Does the weight-loss indication carry different psychiatric risk than the diabetes indication?
Common questions
Do GLP-1 drugs like Ozempic cause depression?
Why does the FDA label warn about suicidal thoughts if studies don't show increased risk?
Read the original research
Glucagon-like peptide receptor agonists and risk for depression.
Primary care diabetes, 18(4), 422-426
Citation
Tagliapietra, Gabriella A; Cantrell, Matthew A; Lund, Brian C. (2024). Glucagon-like peptide receptor agonists and risk for depression.. Primary care diabetes, 18(4), 422-426. https://doi.org/10.1016/j.pcd.2024.05.005